en
Scientific article
English

Rituximab, bendamustine and lenalidomide in patients with aggressive B‐cell lymphoma not eligible for anthracycline‐based therapy or intensive salvage chemotherapy – SAKK 38/08

Published inBritish journal of haematology, vol. 174, no. 2, p. 255-263
Publication date2016-03-28
First online date2016-03-28
Abstract

An increasing number of older patients are suffering from aggressive lymphoma. Effective and more tolerable treatment regimens are urgently needed for this growing patient population. Patients with aggressive lymphoma not eligible for anthracycline‐based first‐line therapy or intensive salvage regimens were treated with the rituximab‐bendamustine‐lenalidomide (R‐ BL ) regimen (rituximab 375 mg/m 2 day 1, bendamustine 70 mg/m 2 d 1, 2, lenalidomide 10 mg d 1–21) for six cycles every 4 weeks. Forty‐one patients with a median age of 75 (range 40–94) years were enrolled: 33 patients had substantial co‐morbidities. 13 patients were not eligible for anthracycline‐based first‐line chemotherapy, 28 patients had relapsed/refractory disease. The primary endpoint, overall response, was achieved by 25 (61%) patients (95% confidence interval 45–76%). Grade ≥ 3 toxicity comprised haematological (59%), skin (15%), constitutional (15%) and neurological (12%) events. 9 patients died during trial treatment: 5 from lymphoma progression, 2 from toxicity, 2 with sudden death. After a median follow‐up of 25·9 (interquartile range 20·4–31·6) months, 13 patients were still alive. Median overall survival was 14·5 months. In conclusion, R‐ BL can be considered a treatment option for elderly patients with treatment naïve or relapsed/refractory aggressive lymphoma not eligible for standard aggressive regimens.

eng
Keywords
  • Aggressive-B cell lymphoma
  • Bendamustine
  • Lenalidomide
  • Relapse
  • Rituximab
Citation (ISO format)
HITZ, Felicitas et al. Rituximab, bendamustine and lenalidomide in patients with aggressive B‐cell lymphoma not eligible for anthracycline‐based therapy or intensive salvage chemotherapy – SAKK 38/08. In: British journal of haematology, 2016, vol. 174, n° 2, p. 255–263. doi: 10.1111/bjh.14049
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal0007-1048
17views
0downloads

Technical informations

Creation12/06/2023 3:23:17 PM
First validation03/20/2024 10:23:37 AM
Update time03/20/2024 10:23:37 AM
Status update03/20/2024 10:23:37 AM
Last indexation03/20/2024 10:23:58 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack